Discovery of Safe COX‐2 Inhibitors: Achieving Reduced Colitis Side Effects through Balanced COX Inhibition
Authors:
- 10 March 2025
- journal article
- Published by Wiley in ChemMedChem
- Vol. 20 (10) , e202500096
Abstract
The severe adverse effects associated with imbalanced cyclooxygenase‐2 (COX‐2) inhibition continue to pose significant challenges in the development of contemporary anti‐inflammatory drugs. In recent years, the approach to COX‐2 inhibitor drug development has shifted from a focus on highly selective inhibition of COX‐2 to a strategy that emphasizes more moderate selectivity. The amino acid sequence and structural similarities between inducible COX‐2 and constitutive cyclooxygenase‐1 (COX‐1) isoforms present both substantial opportunities and challenges for the design of next generation of balanced COX‐2 inhibitors. As part of our ongoing research into the discovering novel and safer COX‐2 inhibitors, we reported herein a highly potent and balanced COX‐2 inhibitor 21 d (IC50 value=1.35 μM, selectivity profile (IC50 (COX‐1)/IC50 (COX‐2)=22.34)). In vivo assays demonstrated that 21 d significantly alleviated histological damage and provided robust protection against dextran sulfate sodium (DSS)‐induced acute colitis.Keywords
This publication has 51 references indexed in Scilit:
- Design of Balanced Cyclooxygenase Inhibitors Based on Natural Anti‐inflammatory Ascidian Metabolites and CelecoxibChemMedChem, 2023
- Recent development on COX-2 inhibitors as promising anti-inflammatory agents: The past 10 yearsActa Pharmaceutica Sinica B, 2022
- Cyanidin-3-O-Glucoside Protects PC12 Cells Against Neuronal Apoptosis Mediated by LPS-Stimulated BV2 Microglial ActivationNeurotoxicity Research, 2019
- Recent advancement in the discovery and development of COX-2 inhibitors: Insight into biological activities and SAR studies (2008–2019)Bioorganic Chemistry, 2019
- Selective cyclooxygenase inhibition and ulcerogenic liability of some newly prepared anti-inflammatory agents having thiazolo[4,5-d]pyrimidine scaffoldBioorganic Chemistry, 2019
- Pyrazoles containing thiophene, thienopyrimidine and thienotriazolopyrimidine as COX-2 selective inhibitors: Design, synthesis, in vivo anti-inflammatory activity, docking and in silico chemo-informatic studiesBioorganic Chemistry, 2019
- Design, synthesis, analgesic, anti-inflammatory activity of novel pyrazolones possessing aminosulfonyl pharmacophore as inhibitors of COX-2/5-LOX enzymes: Histopathological and docking studiesBioorganic Chemistry, 2018
- Non-acidic 1,3,4-trisubstituted-pyrazole derivatives as lonazolac analogs with promising COX-2 selectivity, anti-inflammatory activity and gastric safety profileBioorganic Chemistry, 2018
- New 1,2-diaryl-4-substituted-benzylidene-5-4 H -imidazolone derivatives: Design, synthesis and biological evaluation as potential anti-inflammatory and analgesic agentsBioorganic Chemistry, 2017
- Regulation of IL-6 in Immunity and Diseases2016